

TTA VALVEN

Haemophiliacs 'denied funds for HIV therapy'

by Michael Day

HIV-POSITIVE haemophiliacs are being denied treatment which could add years to their lives, leading consultants claim.

The Department of Health has banned the funding of pure factor VIII anti-clotting agent from money earmarked for the care of AIDS patients.

Regional health directors have been notified of the policy change and already UK haemophilia centres are giving HIV- positive patients what they believe is sub-standard treatment with the impure factor VIII.

Haemophiliacs with HIV are angry, said Dr John Leslie, director of the Norwich and Norfolk Hospital Haematology unit.

'It's crazy. There is a lot of money in the AIDS budget and this cash would be a relevant source for funding the treatment these patients need.'

Dr Christine Lee, director of the Royal Free Hospital's haemophilia unit, agrees: 'By using pure factor VIII we can delay the onset of AIDS, ' she said.

Dr Lee wrote to the *BMJ* in March this year citing 'convincing evidence that high-purity concentrate slows immunological deterioration' in HIV-infected haemophiliacs.

It is thought the numerous antigens present in impure factor VIII further weakens the immune systems of HIV-positive patients by causing other immune reactions.


Controlled trials have shown that in patients treated with pure factor VIII CD4 levels drop

From : Virginia Bottomley M.P.

less quickly than in those treated with the impure factor.

But Dr Paul Walker, public health director at Norwich Health Authority, said: 'We looked at the use of pure factor VIII and decided the evidence of benefit was insubstantial. We had to weigh health gain against cost and we didn't think it was worth it.'

It would cost Norwich Health Authority an extra £24,000 per year to treat Dr Leslie's four HIV-positive haemophiliac patients with the pure agent.



Ho

Epile scan

THE National So lepsy is appealir equip a magnet imaging unit.

It claims the u matically impreand enable more undergo surgery the only hope of

The unit, which puter technology the society, is to headquarters in Peter, Buckingha

The NES says t be the first in th cated to epilepsy believes more th tients a year cou for surgery using nique.

It is estimated 20,000 patients

Resea hope i for or vaccii


ORAL vaccines the effective than the counterparts coreality in the next

Developers of vaccines at Londe College, predict t dose oral cholera developed by the be the first on the

Prof Gordon D

oilim Oral Forms Prescribing Information

1. Epilim: 200 Enteric Coated. A Ital: control of d tablet containing 200mg Sodium Valproate B.P. Enteric Coated. Allia: coloured, enteric coated the use R.P.3 Folim: 100mg nteric Coated Aliac-coloured, enteric coated ing 500mg Sodium Valproate B.P.3.Epilim 100mg blets. A white, scored tablet containing 100mg **DEnteric** Co superts. A white, scored tablet containing fuum Valproate R.P. 4. Epilin Syrup, Ared, herry-fi-up containing 200mg Sodium Valproate R.P. per taining 200mg Sodium Valproate R.P. per taining 200mg Sodium Valproate R.P. per Soliton the treatment of generalized partial or other cepter nen of childbearing age Epilin should be used or eCases or in those ensistant to other treatment. I Mainistration is herefore ever case of in mode resident to their treatment. Design of Administration in the tale-shift are fired fightin may e given twice dails. Enterix coaled tables should be automed which Monetherage Addises shart at 600mg daily creasing by 200mg at 3-Gai intrusts until control is achieved daimum door. 2500mg per dajl. Children one: 200g initially 200mg/chy with spacer increases until control is achieved sets an ab monitored. Mose Mingly get day monitor mical chemistry and haeronating (Children one: 200g initially hidren number 201g; 200mg/tg.body weight per day) hidren number 201g; 200mg/tg.body weight per day, in severe sets may be increased fail only when plasma valprois acid weiss can be monitored. Mose Mingly get day monitor mical chemistry and haeronating/ciparameters. Combined therapt thing the necessary traise the doser when used with incomvisionity and haeronating ciparameters. Combined therapt thing the necessary traise the doser when used with incomvisionity and haeronating strainers. Combined therapt thing the necessary traise the doser when used with incomvisionity and haeronatic typescience control and the measurement of plasmideets is unnecessary. Contro-dications, Warnings: Contro-andicatases. Active for doses the traiter included stapling: a dos sciolum subprotes interts and a straine shifters han distance in plasmost one traitment in cloaded stapling and the original matabolics or generating disorders, organic bian mails et ardistion. The ident trainally occurred during the first foronthy of therapy inotherapy is to be pretended in this googn of patients in the auth stages helpest failure. How a planetary real symptoms are more helpful than lalocatory real stappions, usably and, diventings under. These are an ication no immediate withtawal of the drug. Patients in the auth stages helpest failure, tests which bish which, if any, investigation is practicity tests which is protein synthesis or postilogendum time and be most in the patientian in the start stability be provided by the start trests. To be taken with or after food. En en twice daily. Enteric coated tablets : ed whole. Monotherage Adults: Start at 6 gations second any acceleration in the units of which, if any, investigation is predictive, tests which oten synthesis or growthrowthin time may be nost Routine measuremental liver function should be en before therapy and periodically during the first ant. Routine measuremental liver function should be traken before theragy and particularly during the first nonth's especially in those who seem most at risk, and e with a prior history of liver disease hyperammonaems of hepotic dimage may occur; it is subly transient, but occasionally present chinality. If is Ephilim should be ominaed. Valgrone and inhibits platelet aggregation, mboorytopenia has been reported. Prior to initiation of pay and before suggery chinicians should assure selves that there is no undue potential foo bleeding is an ation for withdrawal of medication. Parcetatis, Iremor, H agin. Unarisent thair loss: increased alertness. ation for withdrawal of medication. Recreating, temor, N. gain, transient hair kau, increased alertness, essiveness, hyperactivity, inregular periods, ornhoa, gunaeconusita, augurandoederna hae been ried. Drug Interactions fipitin may potentiate oleptics, monoamine oxidase inhibitors and other hppressants. Caution is recommended when instering products which has anticogular properties arfann and salicivians. Epilim does not induce liver



On screen . . . trumpeter, vie